Enlivex Therapeutics
ENLV
ENLV
24 hedge funds and large institutions have $3.99M invested in Enlivex Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
3.53% more ownership
Funds ownership: 11.98% → 15.51% (+3.5%)
7% less capital invested
Capital invested by funds: $4.31M → $3.99M (-$321K)
Holders
24
Holding in Top 10
–
Calls
$15K
Puts
$11K
Top Buyers
| 1 | +$742K | |
| 2 | +$98.5K | |
| 3 | +$80.7K | |
| 4 |
Morgan Stanley
New York
|
+$28K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$26.2K |
Top Sellers
| 1 | -$38.1K | |
| 2 | -$23.4K | |
| 3 | -$9.63K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.8K |
| 5 |
SIC
Sigma Investment Counselors
Northville,
Michigan
|
-$2.34K |